vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Ouster, Inc. (OUST). Click either name above to swap in a different company.
Ouster, Inc. is the larger business by last-quarter revenue ($62.2M vs $44.9M, roughly 1.4× AbCellera Biologics Inc.). On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 106.6%). Ouster, Inc. produced more free cash flow last quarter ($-37.2M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 54.8%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Ouster, Inc. is an American lidar technology company headquartered in San Francisco, California. It builds high-resolution, digital 3D lidar sensors for use in autonomous vehicles, industrial, robotics, drones, mapping, defense, and security systems.
ABCL vs OUST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $62.2M |
| Net Profit | $-8.9M | — |
| Gross Margin | — | 60.2% |
| Operating Margin | -63.7% | 1.5% |
| Net Margin | -19.9% | — |
| Revenue YoY | 788.4% | 106.6% |
| Net Profit YoY | 73.9% | — |
| EPS (diluted) | $-0.03 | $0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $62.2M | ||
| Q3 25 | $9.0M | $39.5M | ||
| Q2 25 | $17.1M | $35.0M | ||
| Q1 25 | $4.2M | $32.6M | ||
| Q4 24 | $5.0M | $30.1M | ||
| Q3 24 | $6.5M | $28.1M | ||
| Q2 24 | $7.3M | $27.0M | ||
| Q1 24 | $10.0M | $25.9M |
| Q4 25 | $-8.9M | — | ||
| Q3 25 | $-57.1M | $-21.7M | ||
| Q2 25 | $-34.7M | $-20.6M | ||
| Q1 25 | $-45.6M | $-22.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-51.1M | $-25.6M | ||
| Q2 24 | $-36.9M | $-23.9M | ||
| Q1 24 | $-40.6M | $-23.8M |
| Q4 25 | — | 60.2% | ||
| Q3 25 | — | 42.1% | ||
| Q2 25 | — | 45.2% | ||
| Q1 25 | — | 41.3% | ||
| Q4 24 | — | 43.8% | ||
| Q3 24 | — | 38.3% | ||
| Q2 24 | — | 33.7% | ||
| Q1 24 | — | 28.6% |
| Q4 25 | -63.7% | 1.5% | ||
| Q3 25 | -851.8% | -61.4% | ||
| Q2 25 | -290.2% | -76.5% | ||
| Q1 25 | -1479.6% | -73.0% | ||
| Q4 24 | — | -85.1% | ||
| Q3 24 | -1439.4% | -98.0% | ||
| Q2 24 | -1276.2% | -93.6% | ||
| Q1 24 | -551.5% | -99.5% |
| Q4 25 | -19.9% | — | ||
| Q3 25 | -637.8% | -55.0% | ||
| Q2 25 | -203.3% | -58.8% | ||
| Q1 25 | -1077.2% | -67.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -785.4% | -91.1% | ||
| Q2 24 | -504.3% | -88.4% | ||
| Q1 24 | -408.0% | -91.9% |
| Q4 25 | $-0.03 | $0.10 | ||
| Q3 25 | $-0.19 | $-0.37 | ||
| Q2 25 | $-0.12 | $-0.38 | ||
| Q1 25 | $-0.15 | $-0.42 | ||
| Q4 24 | — | $-0.46 | ||
| Q3 24 | $-0.17 | $-0.54 | ||
| Q2 24 | $-0.13 | $-0.53 | ||
| Q1 24 | $-0.14 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $208.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $261.7M |
| Total Assets | $1.4B | $349.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | $208.6M | ||
| Q3 25 | $83.2M | $244.5M | ||
| Q2 25 | $92.4M | $226.5M | ||
| Q1 25 | $159.3M | $168.2M | ||
| Q4 24 | $156.3M | $172.0M | ||
| Q3 24 | $126.6M | $151.4M | ||
| Q2 24 | $148.3M | $184.2M | ||
| Q1 24 | $123.6M | $187.8M |
| Q4 25 | $966.9M | $261.7M | ||
| Q3 25 | $964.0M | $247.4M | ||
| Q2 25 | $1.0B | $221.0M | ||
| Q1 25 | $1.0B | $167.9M | ||
| Q4 24 | $1.1B | $180.9M | ||
| Q3 24 | $1.1B | $171.7M | ||
| Q2 24 | $1.1B | $170.6M | ||
| Q1 24 | $1.1B | $167.2M |
| Q4 25 | $1.4B | $349.5M | ||
| Q3 25 | $1.4B | $353.8M | ||
| Q2 25 | $1.4B | $321.8M | ||
| Q1 25 | $1.3B | $268.6M | ||
| Q4 24 | $1.4B | $276.1M | ||
| Q3 24 | $1.4B | $255.2M | ||
| Q2 24 | $1.4B | $309.9M | ||
| Q1 24 | $1.5B | $317.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $-15.4M |
| Free Cash FlowOCF − Capex | $-44.6M | $-37.2M |
| FCF MarginFCF / Revenue | -99.4% | -59.8% |
| Capex IntensityCapex / Revenue | 21.9% | 35.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $-64.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $-15.4M | ||
| Q3 25 | $-52.6M | $-18.3M | ||
| Q2 25 | $-32.4M | $-1.3M | ||
| Q1 25 | $-11.6M | $-4.9M | ||
| Q4 24 | $-108.6M | $-2.6M | ||
| Q3 24 | $-28.9M | $-3.8M | ||
| Q2 24 | $-30.0M | $-21.6M | ||
| Q1 24 | $-41.7M | $-5.7M |
| Q4 25 | $-44.6M | $-37.2M | ||
| Q3 25 | $-61.5M | $-20.0M | ||
| Q2 25 | $-45.8M | $-2.2M | ||
| Q1 25 | $-22.2M | $-5.4M | ||
| Q4 24 | $-187.0M | $-4.0M | ||
| Q3 24 | $-47.4M | $-4.3M | ||
| Q2 24 | $-50.1M | $-22.0M | ||
| Q1 24 | $-65.8M | $-7.1M |
| Q4 25 | -99.4% | -59.8% | ||
| Q3 25 | -687.0% | -50.7% | ||
| Q2 25 | -267.9% | -6.3% | ||
| Q1 25 | -524.0% | -16.6% | ||
| Q4 24 | -3702.8% | -13.3% | ||
| Q3 24 | -728.4% | -15.4% | ||
| Q2 24 | -683.8% | -81.5% | ||
| Q1 24 | -661.5% | -27.4% |
| Q4 25 | 21.9% | 35.0% | ||
| Q3 25 | 99.7% | 4.3% | ||
| Q2 25 | 78.2% | 2.5% | ||
| Q1 25 | 251.1% | 1.7% | ||
| Q4 24 | 1552.7% | 4.8% | ||
| Q3 24 | 284.6% | 2.0% | ||
| Q2 24 | 274.6% | 1.3% | ||
| Q1 24 | 242.5% | 5.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
